A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia
Noelle V. Frey(Hospital of the University of Pennsylvania), Martin Carroll(University of Pennsylvania), James K. Mangan(UC San Diego Health System), Marlise R. Luskin(Dana-Farber Cancer Institute), Hans Minderman(Roswell Park Comprehensive Cancer Center), Alexander E. Perl(University of Pennsylvania), Alison W. Loren(University of Pennsylvania), John H. Baird(City Of Hope National Medical Center), Alexis Zebrowski(University of Pennsylvania), Elizabeth O. Hexner(University of Pennsylvania), Selina M. Luger(University of Pennsylvania), David Porter(University of Pennsylvania), Anita J. Kumar(University of Pennsylvania)
Cited by 14
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k